TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29538626

Group type: EXPERIMENTAL
Intervention: HINTS intervention
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study: 27259568

Group type: EXPERIMENTAL
Intervention: Standardised programming protocol (long detection times of 30/40 or equivalent and high rate detection zones of 200 bpm)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Standardised programming protocol
Number of subjects: 270

Group type: COMPARATOR
Intervention: Physician-led group
Number of subjects: 270
Study: 24885437

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 152

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 152
Study: 22549390

Group type: EXPERIMENTAL
Intervention: Jiedu granules plus cinobufacini injection (CM group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE group)
Number of subjects: 120
Study: 20353469

Group type: EXPERIMENTAL
Intervention: 200 days valganciclovir prophylaxis (900 mg once daily)
Number of subjects: 326

Group type: COMPARATOR
Intervention: 100 days valganciclovir prophylaxis (900 mg once daily)
Number of subjects: 326
Study: 18419349

Group type: EXPERIMENTAL
Intervention: High-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine
Number of subjects: 1395
Study: 15863796

Group type: EXPERIMENTAL
Intervention: 10 mg i.m. of olanzapine
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 7.5 mg i.m. of haloperidol
Number of subjects: 311

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 311
Study: 11862501

Group type: EXPERIMENTAL
Intervention: Supportive care plus MLT (20 mg/day orally during the dark period)
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus MLT (20 mg/day orally during the dark period)
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1640
Study: 10350950

Group type: EXPERIMENTAL
Intervention: Group mean centering
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard analysis of covariance (ANCOVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analyzing each site separately
Number of subjects: 0
Study: 7586608

Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg i.v.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms/kg i.v.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hexarelin + Naloxone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1918275

Group type: EXPERIMENTAL
Intervention: Intravenous urokinase (UK) 72,000 IU injected over 10 minutes and UK 528,000 IU by drip infusion over 12 or 24 hours (UK group, n = 76)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional therapy without urokinase (control group, n = 90)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Intravenous urokinase (UK) (UK group, n = 43)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional therapy without urokinase (control group, n = 32)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Intravenous urokinase (UK) (UK group, n = 66)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional therapy without urokinase (control group, n = 68)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Intravenous urokinase (UK) (UK group, n = 10)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional therapy without urokinase (control group, n = 22)
Number of subjects: 166
Study: 6130665

Group type: EXPERIMENTAL
Intervention: Continuation of ordinary therapy until planned cholecystectomy under neurolept anaesthesia (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 4-day gradual withdrawal of beta-receptor blockers (n = 13)
Number of subjects: 26
Study: 30300265

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Releasable scleral buckling (RSB)
Number of subjects: 110
Study: 31163519

Group type: EXPERIMENTAL
Intervention: Methylprednisolone combined with peripheral vestibular rehabilitation therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methylprednisolone only (Control)
Number of subjects: 50
Study: 28893134

Group type: EXPERIMENTAL
Intervention: Mepolizumab (100 mg)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462

Group type: COMPARATOR
Intervention: Mepolizumab (100 mg) vs Placebo
Number of subjects: 462

Group type: COMPARATOR
Intervention: Mepolizumab (300 mg) vs Placebo
Number of subjects: 462

Group type: COMPARATOR
Intervention: Overall modified intention-to-treat population
Number of subjects: 462
Study: 27808277

Group type: EXPERIMENTAL
Intervention: Kidney surface cooling (ice bag technique, IBT group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard technique (control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Kidney surface cooling (IBT group)
Number of subjects: 23
Study: 23417600

Group type: EXPERIMENTAL
Intervention: cAAI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AAI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 45
Study: 21483000

Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 529

Group type: COMPARATOR
Intervention: Fludarabine with or without cyclophosphamide
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 529
Study: 19299681

Group type: EXPERIMENTAL
Intervention: IMCI training plus study supports (job aids, nonfinancial incentives, and supervision)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: IMCI training plus usual supports
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Untrained workers
Number of subjects: 1244
Study: 17561044

Group type: EXPERIMENTAL
Intervention: Cepacol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Periogard
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sterile tap water
Number of subjects: 17
Study: 15581523

Group type: EXPERIMENTAL
Intervention: Safer Choices intervention
Number of subjects: 3869

Group type: COMPARATOR
Intervention: Standard knowledge-based HIV-education program
Number of subjects: 3869
Study: 11234601

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 45
Study: 9649009

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (various regimens including intravenous mitomycin plus 5‐fluorouracil, oral 5‐FU, intravenous methotrexate plus 5‐FU, intravenous cisplatin plus 5‐FU, hepatic arterial infusion of 5‐FU plus oral 5‐FU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no postoperative chemotherapy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 100
Study: 7517720

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) as a single agent before conventional remission induction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as acute nonlymphoblastic leukemia (ANLL) blasts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study: 2915237

Group type: EXPERIMENTAL
Intervention: Implantable ports
Number of subjects: 264

Group type: COMPARATOR
Intervention: Broviac catheters
Number of subjects: 264

Group type: COMPARATOR
Intervention: Hickman catheters
Number of subjects: 264
Study: 31937026

Group type: EXPERIMENTAL
Intervention: Holistic nursing (experimental group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional nursing (control group)
Number of subjects: 120
Study: 27640142

Group type: EXPERIMENTAL
Intervention: Piezoelectric device
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 90
Study: 25392337

Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation group (PRG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional rehabilitation group (TRG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (PRG and TRG)
Number of subjects: 32
Study: 23517517

Group type: EXPERIMENTAL
Intervention: Daily handwashing with soap, daily brushing with fluoride toothpaste, biannual deworming with 400 mg albendazole (Essential Health Care Program [EHCP])
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group (external concurrent control)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Group 1 (EHCP)
Number of subjects: 412
Study: 21410861

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 42

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 42
Study: 18599554

Group type: EXPERIMENTAL
Intervention: rs1151640 polymorphism in the OR13G1 gene
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: rs11881940 polymorphism in the HNRPUL1 gene
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: rs3746731 polymorphism in the CD93 gene
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: rs10757274 polymorphism near the CDKN2A and CDKN2B genes
Number of subjects: 2145
Study: 16783467

Group type: EXPERIMENTAL
Intervention: Infusion rate of IGIV-C, 10% at 0.14 mL/kg/min
Number of subjects: 97

Group type: COMPARATOR
Intervention: Infusion rate of IGIV-C, 10% at 0.08 mL/kg/min (standard rate)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both rates of infusion (0.08 mL/kg/min and 0.14 mL/kg/min)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Increased rate of infusion of IGIV-C, 10%
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Increased rate of infusion of IGIV-C, 10% at 0.14 mL/kg/min
Number of subjects: 97
Study: 14564363

Group type: EXPERIMENTAL
Intervention: Peach allergy confirmed by double-blind, placebo-controlled food challenges
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Skin prick tests with fresh peach and purified peach LTP (Pru p 3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Specific IgE determinations to peach, rBet v 1, and rBet v 2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of sensitization rates
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IgE responses to rBet v 2
Number of subjects: 100
Study: 11712301

Group type: EXPERIMENTAL
Intervention: Pre-term newborns
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Newborns with congenital heart defects
Number of subjects: 114

Group type: COMPARATOR
Intervention: Full-term newborns
Number of subjects: 114
Study: 8705098

Group type: EXPERIMENTAL
Intervention: Early postoperative breast feeding
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spoon feeding
Number of subjects: 40
Study: 1642915

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG) 200 micrograms
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 1,600 micrograms
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG) and Isosorbide dinitrate (ISDN)
Number of subjects: 32
Study: 7021412

Group type: EXPERIMENTAL
Intervention: Kallikrein treatment
Number of subjects: 20
Study: 30190369

Group type: EXPERIMENTAL
Intervention: Sorafenib + modified FOLFOX (sorafenib 400 mg twice a day for 2 weeks, followed by mFOLFOX: 5-FU 1200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, oxaliplatin 85 mg/m2 biweekly)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 40
Study: 27908967

Group type: EXPERIMENTAL
Intervention: 18F‐AV‐1451
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SUVR calculated over an imaging window of 80‐100 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cortical SUVR curves
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Distribution volume (130 min)
Number of subjects: 16
Study: 25473939

Group type: EXPERIMENTAL
Intervention: AZD5423 (75 or 300 μg) once daily for 7 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AZD5423 (300 μg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AZD5423 (75 μg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Budesonide (200 μg twice daily)
Number of subjects: 20
Study: 24221838

Group type: EXPERIMENTAL
Intervention: In-hospital treatments for AMI
Number of subjects: 18000
Study: 21402409

Group type: EXPERIMENTAL
Intervention: Depressive symptoms during pregnancy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Pregnancy intention
Number of subjects: 217
Study: 19772502

Group type: EXPERIMENTAL
Intervention: Indapamide retard therapy for 8 weeks
Number of subjects: 0
Study: 17519152

Group type: EXPERIMENTAL
Intervention: CARRA/LNG containing 0.75 mg LNG per 4 mL of gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CARRA/LNG containing 1.5 mg LNG per 4 mL of gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both doses of CARRA/LNG
Number of subjects: 12
Study: 15219640

Group type: EXPERIMENTAL
Intervention: Propranolol pre-treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo pre-treatment
Number of subjects: 16
Study: 11579345

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 9642484

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs) with pravastatin (lipid-lowering therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin (lipid-lowering therapy)
Number of subjects: 0
Study: 8124699

Group type: EXPERIMENTAL
Intervention: Intensive fluoride varnish program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard biannual fluoride varnish program
Number of subjects: 100
Study: 2528022

Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive therapy (prednisone, cyclophosphamide, azathioprine)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Membrane plasmapheresis (in addition to immunosuppressive therapy)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No specific therapy
Number of subjects: 31
Study: 791477

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and vincristine (CV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, and procarbazine (CVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with disease confined to skin, subcutaneous tissue nodes, lung, or pleura
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 0
Study: 30037818

Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg with abiraterone 1,000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipatasertib 200 mg with abiraterone 1,000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with abiraterone 1,000 mg
Number of subjects: 0
Study: 28182502

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (140ml, 12.5mmol nitrate)
Number of subjects: 10
Study: 25627092

Group type: EXPERIMENTAL
Intervention: hybrid‐CIMT (n=25)
Number of subjects: 53

Group type: COMPARATOR
Intervention: standard care (n=19)
Number of subjects: 53
Study: 24094463

Group type: EXPERIMENTAL
Intervention: Test formulation of AT-III 100 U/kg IV for 20 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of AT-III 100 U/kg IV for 20 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study: 20924596

Group type: EXPERIMENTAL
Intervention: Soccer training (SOC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-intensity interval running (INT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Continuous running (RUN)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study: 19453044

Group type: EXPERIMENTAL
Intervention: Modified Sugiura procedure
Number of subjects: 51

Group type: COMPARATOR
Intervention: Simplified Sugiura procedure
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 51
Study: 18086050

Group type: EXPERIMENTAL
Intervention: smooth-gel hyaluronic acid dermal fillers
Number of subjects: 439

Group type: COMPARATOR
Intervention: cross-linked bovine collagen
Number of subjects: 439
Study: 15537681

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1000 mg)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 11887498

Group type: EXPERIMENTAL
Intervention: High frequency oscillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids administered systemically in the first two weeks after birth
Number of subjects: 0
Study: 9632998

Group type: EXPERIMENTAL
Intervention: Potent combination antiretroviral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole or alternative agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Specific antimicrobial prophylaxis for MAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylaxis for PCP, disseminated MAC infection, and CMV end-organ disease
Number of subjects: 0
Study: 7912876

Group type: EXPERIMENTAL
Intervention: Dixyrazine (15-30 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam (4-10 mg)
Number of subjects: 100
Study: 2510135

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg every 8 hours for 5 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Encainide 25 mg every 8 hours for 5 days
Number of subjects: 9
Study: 1254724

Group type: EXPERIMENTAL
Intervention: Gastrin antiserum (0.02, 0.1, and 0.5 ml/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic human gastrin I (0.25 mug-kg-1-h-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastrin antiserum (0.1 ml/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastrin antiserum (0.2 ml/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control antiserum
Number of subjects: 0
Study: 31343936

Group type: EXPERIMENTAL
Intervention: Baseline condition of the Tower of London task
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Articulatory suppression secondary task (disrupted verbal mediation)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Motor suppression secondary task (control for secondary task demand)
Number of subjects: 81
Study: 28627793

Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: phenylephrine
Number of subjects: 20
Study: 27045264

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily (OaD)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg on-demand (PRN)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 22998616

Group type: EXPERIMENTAL
Intervention: 1 implant (Group 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 implants (Group 2)
Number of subjects: 36
Study: 22971152

Group type: EXPERIMENTAL
Intervention: Awareness program as part of the SEYLE intervention study
Number of subjects: 0
Study: 20680193

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 34
Study: 18198454

Group type: EXPERIMENTAL
Intervention: CBBD scale applied to caregivers of care-recipients with cognitive disorders
Number of subjects: 1818

Group type: COMPARATOR
Intervention: CBBD scale applied to caregivers of care-recipients without cognitive disorders
Number of subjects: 1818

Group type: EXPERIMENTAL
Intervention: CBBD scale items related to symptoms of dementia
Number of subjects: 1818
Study: 16253026

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy
Number of subjects: 28
Study: 12390389

Group type: EXPERIMENTAL
Intervention: Palliative resection
Number of subjects: 285
Study: 10444231

Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg/day)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Mizolastine (5-45 mg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: First generation antihistamines (clemastine, tripolidine) and second generation antihistamines (terfenadine, cetirizine)
Number of subjects: 91
Study: 7842761

Group type: EXPERIMENTAL
Intervention: 2-month reevaluation interval
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6-month reevaluation interval
Number of subjects: 50
Study: 1978488

Group type: EXPERIMENTAL
Intervention: Remoxipride (30-90 mg, 120-240 mg, 300-600 mg, divided into three doses per day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Remoxipride (maximum dose for 4 weeks or more)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Remoxipride (dose reductions or discontinuations due to adverse symptoms)
Number of subjects: 79
Study: 792736

Group type: EXPERIMENTAL
Intervention: parsalmide
Number of subjects: 40

Group type: COMPARATOR
Intervention: indomethacin
Number of subjects: 40
Study: 31190491

Group type: EXPERIMENTAL
Intervention: Tiaoren Tongdu acupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Femoston (oral estradiol and dydrogesterone tablets)
Number of subjects: 50
Study: 29246219

Group type: EXPERIMENTAL
Intervention: 100 mg of Pycnogenol® twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 33
Study: 25937516

Group type: EXPERIMENTAL
Intervention: Active and Healthy Families (AHF)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care wait-list control
Number of subjects: 55
Study: 22688211

Group type: EXPERIMENTAL
Intervention: Brain Injury Partners program (Web-based intervention)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 22097612

Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg/d
Number of subjects: 65

Group type: COMPARATOR
Intervention: Adefovir dipivoxil 10 mg/d
Number of subjects: 65
Study: 19819095

Group type: EXPERIMENTAL
Intervention: Implicit language used by physicians when delivering bad news
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Implicit language in bad news delivery
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Understanding of bad news by patients
Number of subjects: 16
Study: 16537846

Group type: COMPARATOR
Intervention: Tiotropium alone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tiotropium plus formoterol once daily
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tiotropium plus formoterol twice daily
Number of subjects: 95
Study: 12492791

Group type: EXPERIMENTAL
Intervention: Bupivacaine 6.0 mg + fentanyl 25 micro g
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine 7.5 mg + fentanyl 25 micro g
Number of subjects: 40